Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Sznaidman, Marcos L (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C435S375000
Reexamination Certificate
active
08008346
ABSTRACT:
The present invention relates to a anti-proliferative target for designing chemotherapeutic agents, which comprises a EIF4A protein having an amino acid sequence, as defined in claim1.
REFERENCES:
Kassam (Expert Opinion on Emerging Drugs (2008) 13:323-343).
Gonzalez (Tetrahedron (2001) 57:3487-3497).
Gura et. al. (Science, 1997, 278:1041-1042).
Johnson et. al. (British Journal of Cancer, 2001, 84:1424-1431).
Shen, Y.-C., et al., Bioactive steroids from the Formosan Gorgonian Isis Hippuris, Chinese Pharm. J. 2000, 341-351, 52.
Bordeleau, M.E., et al., Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A, Nat. Chem. Biol. 2006, 213-220, 2.
Chao, C.-H., et al., Polyoxygenated steroids from the gorgonian Isis hippuris, J. Nat. Prod., 2005, 880-885, 68.
Higa, T. et al., Hippuristanols, cytotoxic polyoxygenated steroids from the gorgonian Isis hippuris. Chem Lett., 1981, 1647-1650, 11.
Adwankar, M., et al., Combination chemotherapy of early and advanced murine P388 leukaemia with bouvardin, cis-diamminedichloroplatinum and vincristine. Oncology, 1984, 370-373, 41.
Ahuja, D., et al., Inhibition of protein synthesis by didemnins: cell potency and SAR, J. Med. Chem. 2000, 4212-4218, 43.
Ahuja, D., et al., Inhibition of protein synthesis by didemnin B: how EF-I alpha mediates inhibition of translocation. Biochemistry, 2000, 4339-4346, 39.
Andrus, L., et al., Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: a hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-I). Biochem. Pharmacol., 1998, 1807-1818, 55.
Antony, M., et al., Inhibition of mouse skin tumor promotion by tenuazonic acid. Cancer Lett, 1991 21-25, 61.
Benz, J., et al., Crystal structure of the ATPase domain of translation initiation factor 4A fromSaccharomyces cerevisiae—the prototype of the Dead box protein family. Structure Fold. Des. 1999, 671-679, 7.
Bernstein, H. D., et al., Poliovirus mutant that does not selectively inhibit host cell protein synthesis. Mol Cell Biol 1985, 2913-2923, 5.
Caruthers, J. M., et al. Crystal structure of yeast initiation factor 4A, a Dead-box RNA helicase. Proc Natl Acad Sci U S A, 2000, 13080-13085, 97.
Chan, C. C, et al., eIF4A3 is a novel component of the exon junction complex. RNA, 2004, 200-209, 10.
Conroy, S. C, et al., Characterization of the 46,000-dalton subunit of elF-4F. Arch Biochem Biophys, 1990, 363-371, 282.
Dong, Z., et al., Role of eIF3 pI70 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene, 2004, 3790-3801, 21.
Ferraiuolo, M. A. et al., A nuclear translation-like factor eIF4AIII is recruited to the mRNA during splicing and functions in nonsense—mediated decay. Proc Natl Acad Sci U S A, 2004, 4118-4123, 101.
Gonzalez, N., et al., New cytotoxic steroids from the gorgonian Isis hippuris. Structure-activity studies. Tetrahedron 2001, 3487-3497, 57.
Grifo, J.A., et al., RNA-stimulated ATPase activity of eukaryotic initiation factors. J Biol Chem, 1984, 8648-8654, 259.
Grollman, A.P. Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J. Biol. Chem. 1967, 3226-3233, 242.
Hanauske-Abel, H.M., et al., Inhibition of the GI-S transition of the cell cycle by inhibitors of deoxyhypusine hydroxylation. Biochim Biophys Acta 1994, 115-24, 1221.
Hershey, J. W. B., and Merrick, W. C., Initiation of Protein Synthesis. Cold Spring Habor Laboratory Press, 2000, Cold Spring Harbor.
Hershey, J. W. B., and Miyamoto, S., Translational control and Cancer. Cold Spring Habor Laboratory Press, 2000, Cold Spring Harbor.
Heys, S.D., et al. Measurement of tumour protein synthesis in vivo in human colorectal and breast cancer and its variability in separate biopsies from the same tumour. Clin Sci (Lond), 1991, 587-593, 80.
Higa, T., and Tanaka, J., Hippuristanols, cytotoxic polyoxygenated steroids from the Gorgonian Isis Hipuris, Chemistry Letters, 1981, 1647-1650.
Higa, T., et al., 18-oxygenated polyfunctional steriods from the gorgonian Isis hippuris. Tetrahed. Lett., 1981, 2777-2780, 22.
Hofs, H.P., et al., Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia. Anticancer Res, 1992, 167-170, 12.
Hofs, H.P., et al., Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice. Eur J Cancer, 1995, 1526-1530, 9.
Johnson, E.R. and McKay, D.B., Crystallographic structure of the amino terminal domain of yeast initiation factor 4A, a representative Dead-box RNA helicase. RNA 1999, 1526-1534, 5.
Kaczka, E. A., et al., Discovery of inhibitory activity of tenuazonic acid for growth of human adenocarcinoma-1. Biochem Biophys Res Commun. 1964, 54-57, 14.
Kantarjian, H. M., et al., Homoharringtonine: history, current research, and future direction. Cancer, 2001, 1591-605, 92.
Lorsch, J. R., and Herschlag, D., The Dead box protein eIF4A. A cycle of nucleotide and RNA-dependent conformational changes. Biochemistry, 1998, 2194-2206, 37.
Lorsch, J. R., and Herschlag, D., The Dead box protein eIF4A. A minimal kinetic and thermodynamic framework reveals coupled binding of RNA and nucleotide. Biochemistry, 1998 2180-2193, 37.
Muller, H.J., and Boos, J., Use of L-asparaginase in childhood ALL., Crit Rev Oncol Hematol, 1998, 97-113, 28.
Neshat, M.S., et al., Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A, 2001, 10314-10319, 98.
Novac, O., et al., Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res, 2004, 902-915, 32.
Ottenheijm, H.C, and Van Den Broeck, L.A., The development of sparsomycin as an anti-tumour drug. Anticancer Drug Des, 1998, 333-337, 2.
Palacios, I.M., et al., An eIF4AIII-containing complex required for mRNA localization and nonsense-mediated mRNA decay. Nature, 2004, 427:753-757.
Pause, A., et al., Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature, 1994, 371:762-767.
Yoder-Hill, J., et al., The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A. J Biol Chem 1993, 5566-5573, 268.
Zalacain, M., et al., The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells. FEBS Lett 1982, 95-97, 148.
Zalatnai, A., and Bocsi, J. Mimosine, a plant-derived amino acid induces apoptosis in human pancreatic cancer xenografts. Anticancer Res, 2003, 4007-4009, 23.
Chitnis, M.R. et al. Inhibition of macromolecular synthesis in P388 mouse leukemia ascites cells by bouvardin (NSC 259968). Tumori 1985, 71:261-6.
Shibuya, T.T.O. Tet al. eIF4AIII binds spliced mRNA in the exon junction complex and is essential for nonsense-mediated decay. Nat Struct Mol Biol 2004, 11:346-51.
Sonenberg, N. ATP/Mg++-dependent cross-linking of cap binding proteins to the 5′ end of eukaryotic mRNA. Nucleic Acids Res. 1981, 9: 1643-56.
Pause, A., et al., Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and cap-independent initiation of translation. Embo J., 1994 1205-1215, 13.
Pause. A., and Sonenberg. N. Mutational analysis of a Dead box RNA helicase: the mammalian translation initiation factor eIF-4A. Embo J., 1992, 2643-2654, 11.
Pisarev, A.V., et al., Functional and structural similarities between the internal ribosome entry sites of hepatitis C virus and porcine teschovirus, a picornavirus. J Virol, 2004 4487-4497, 78.
Podsypanina, K., et al., An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc Natl Acad Sci U S A. 2001, 10320-10325, 98.
Poulin, F., et al.. 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J Biol Chem, 1998, 14002-14007, 273.
Rao, C. B., et al., Metabolites of the gorgonian Isis hippuris from India. J. Nat. Products. 1988, 51:954-958.
Ray, B.K., et al., ATP-dependent unwinding of messenger RNA structure by eukaryotic initiation factors. J Biol Chem, 1985, 7651-7658, 260.
Richter-Cook, N.J., et al., Purification
Bordeleau Marie-Ève
Francis Robert
Lindqvist Lisa
Pelletier Jerry
Tanaka Junichi
Sznaidman Marcos L
The Royal University for the Advancement of Learning/McGill Univ
LandOfFree
Chemotherapeutic agents for inhibition of protein translation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemotherapeutic agents for inhibition of protein translation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemotherapeutic agents for inhibition of protein translation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702690